Evoke Pharma Inc (NASDAQ:EVOK) continues to move up in the pre-market session on Tuesday. The stock is up 19% over the past month.
Evoke Pharma and EVERSANA Announce Positive Findings from Second GIMOTI® Market Research Study
- today announced positive findings from a second market research study conducted for GIMOTI® (metoclopramide) nasal spray. The study aimed to gather further market insights on the perception of GIMOTI in the GI community and follows the initial market research study conducted in December 2020.
- The Company will discuss the findings in roundtable discussions at the upcoming GI ReConnect Conference, a leadership summit for sharing the most current information on GI health, being held on June 18-19th in Napa Valley, CA.
- In May 2021, Evoke’s commercialization partner, EVERSANA, conducted the GIMOTI Awareness, Trial, Usage (ATU) Study, a quantitative survey designed to measure physician awareness, trial, and product usage of GIMOTI. The ATU survey was divided into four sections: the current approach to treating diabetic gastroparesis (DGP), prescribing behavior, treatment awareness, and additional perspectives around support resources.
- The respondent mix included 67 gastroenterologists (GIs) currently being called on by the field sales force, and an additional 50 GIs and primary care physicians (PCPs), who are not currently targeted for in person messaging, but whom may be targeted through our online digital and social campaign. The study objectives were to understand the current gastroparesis treatment landscape and to evaluate physicians’ perceptions of GIMOTI following recent brand marketing efforts.
As of 9:01, EVOK is trading at $1.46, up 2.82%. So far more than 176K shares have exchanged hands.